Citations

Showing 10 of 108162 citations.

152 Inflatable Penile Prosthesis Infections: Are We Covered?
White, Lindsay A. , Wen, Lexiaochuan , Ziegelmann, Matt, Trost, L., Köhler, Tobias , Yang, David Y. , Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | March 18, 2021 | Volume: 18 | Issue: Supplement_1 | Pages: S82-S82

10.1016/j.jsxm.2021.01.007 Get It

Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after TREAT trial showed they are ineffective and unsafe
Vu, Khoa , Zhou, Jiani , Everhart, Alexander , Jena, Anupam B. , Karaca‐Mandic, Pinar , Desai, Nihar R. , Herrin, Jeph , Ross, Joseph S. , Shah, Nilay

Mayo Clinic

No container title available | March 18, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-329817/v1 Get It

Abstract Variation in de-adoption of ineffective or unsafe treatments is not well-understood. We examined de-adoption of erythropoiesis-stimulating agents (ESA) in anemia treatment among patients with chronic kidney diseases (CKD) following new clinical evidence of harm and ineffectiveness (the TREAT trial) and the FDA's revision of its safety warning. We used an interrupted time series approach to estimate changes in use of epoetin alfa (EPO) and darbepoetin alfa (DPO) in the commercial and Medicare Advantage (MA) and Medicare fee-for-service (FFS) populations. We also examined how changes in both trends and levels of use were associated with physicians’ characteristics. Study cohort included patients with CKD stages 3 to 5 during 2007-2015. Use of DPO and EPO declined over the study period. There were no consistent changes in DPO trend across insurance groups, but the level of DPO use decreased right after the FDA revision in all groups. The decline in EPO use trend was faster after the TREAT trial for all groups. Nephrologists were largely more responsive to evidence than primary care physicians. Differences by physician's gender, and age were not consistent across insurance populations and types of ESA.
Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
Rheenen, Wouter van , Spek, Rick van der, Berg, Leonard van den, Hop, Paul , Zwamborn, Ramona, Klein, Niek de , Westra, Harm-Jan , Bakker, Olivier, Shireby, Gemma , Dolzhenko, Egor, Dekker, Annelot, Westeneng, Henk-Jan, Tazelaar, Gijs, Eijk, Kristel van , Kooyman, Maarten , Doherty, Mark, Iacoangeli, Alfredo, Cooper‐Knock, Johnathan , Smith, Bradley , Chandran, Siddharthan , Morrison, Karen, Shaw, Pamela, Hardy, John , Orrell, Richard, Basak, Nazli, Ratti, Antonia, Pinter, Guiseppe Lauria, D'Alfonso, Sandra, Soraru, Gianni, Padovani, Alessandro , Moglia, Cristina, Brunetti, Maura, Canosa, Antonio, Grassano, Maurizio, Nefussy, Beatrice, Nordin, Angelica, Lerner, Yossef, Zabari, Michal, Baloh, Robert, Bell, Shaugn, Vourc'h, Patrick, Corcia, Philippe, Couratier, Philippe, Meininger, Vincent, Salachas, Francois, Pardina, Jesús Mora, Assialioui, Abdelilah , Rojas‐García, Ricardo , Dion, Patrick, Ludolph, Albert, Weishaupt, Jochen, Brenner, David, Freischmidt, Axel , Bensimon, Gilbert , Durr, Alexandra, Payan, Christine, Saker-Delye, Safa, Wood, Nicholas , Rademakers, Rosa, Tittmann, Lukas, Lieb, Wolfgang, Braun, Alice, Hofman, Albert, Cichon, Sven , Traynor, Bryan, Singleton, Andrew, Neto, Miguel Mitne, Ophoff, Roel, Wiedau-Pazos, Martina, Lomen-Hoerth, Catherine, Rödiger, Annekathrin, Jörk, Alexander, Barthel, Tabea, Theele, Erik, Ilse, Berjamin, Stubendorff, Beatrice, Witte, Otto W. , Hübner, Christian, Graff, Caroline , Brylev, Lev, Fominykh, Vera, Demeshonok, Vera, Ataulina, Anastasia , Koritnik, Blaž , Zidar, Janez , Ravnik-Glavač, Metka, Glavač, Damjan, Stević, Zorica, Drory, Vivian, Povedano, Mónica, Henderson, Robert , Furlong, Sarah , McCombe, Pamela, Ngo, Shyuan, Steyn, Frederik, Mather, Karen A. , Sachdev, Perminder S. , Henders, Anjali, Carvalho, Mamede de, Petri, Susanne, Weber, Markus , Glass, Jonathan D. , Brown, Robert, Landers, John, Garton, Fleur, McRae, Allan, Mill, Jonathan , Kenna, Kevin, Runz, Heiko, Franke, Lude , Damme, Philip Van , Gaur, Nayana , Steyn, Frederik J. , Landers, John E. , Westra, Harm-Jan , Steyn, F J , Cichon, Sven , Sachdev, Perminder S , Van Damme, Philip , Hardy, John , Padovani, Alessandro , Graff, Caroline , Spek, Rick A. A. van der , Bakker, Mark K. , Veldink, Jan H. , Vugt, Joke J.F.A. van , Zwamborn, Ramona A.J. , Deelen, Patrick , Hannon, Eilís , Moisse, Matthieu , Baird, Denis A. , Restuadi, Restuadi , Gawor, Klara , Westeneng, Henk‐Jan , Byrne, Ross Patrick , Heverin, Mark , Khleifat, Ahmad Al , Iacoangeli, Alfredo , Shatunov, Aleksey , Ticozzi, Nicola , Gromicho, Marta , Pal, Suvankar , Orrell, Richard W., Sendtner, Michael , Meyer, Thomas , Basak, Nazli A., Kooi, Anneke J. van der , Ratti, Antonia , Fogh, Isabella , Gellera, Cinzia , Corti, Stefania Paola , Cereda, Cristina , Sproviero, Daisy , D’Alfonso, Sandra , Siciliano, Gabriele , Filosto, Massimiliano , Chiò, Adriano , Calvo, Andrea , Moglia, Cristina , Brunetti, Maura , Canosa, Antonio , Grassano, Maurizio , Beghi, Ettore , Pupillo, Elisabetta , Logroscino, Giancarlo , Osmanovic, Alma , Nordin, Angelica , Lerner, Yossef, Zabari, Michal, Gotkine, Marc , Vourc’h, Patrick , Corcia, Philippe , Couratier, Philippe , Millecamps, Stéphanie , Meininger, Vincent, Salachas, François, Ross, Jay P. , Ludolph, Albert, Brice, Alexis , Dürr, Alexandra , Saker-Delye, Safaa, Wood, Nicholas , Topp, Simon , Rademakers, Rosa , Tittmann, Lukas , Franke, André , Ripke, Stephan , Braun, Alice , Kraft, Julia , Whiteman, David C. , Olsen, Catherine M. , Uitterlinden, André G. , Hofman, Albert, Rietschel, Marcella , Nöthen, Markus M. , Amouyel, Philippe , Traynor, Bryan J. , Singleton, Andrew, Cauchi, Ruben J. , Ophoff, Roel A. , Lomen‐Hoerth, Catherine , Deerlin, Vivianna M. Van , Großkreutz, Julian , Rödiger, Annekathrin, Jörk, Alexander, Barthel, Tabea, Theele, Erik, Steinbach, Robert , Hübner, Christian, Fominykh, Vera , Demeshonok, Vera, Rogelj, Boris , Drory, Vivian, Blair, Ian P. , Kiernan, Matthew C. , Benyamin, Beben , Mathers, Susan , Needham, Merrilee , Ngo, Shyuan T. , Nicholson, Garth A. , Pamphlett, Roger , Rowe, Dominic B. , Williams, Kelly L. , Wallace, Leanne M. , Carvalho, Mamede A. de , Pinto, Susana , Petri, Susanne , Rouleau, Guy Armand , Silani, Vincenzo , Curtis, Charles J. C. , Breen, Gerome , Brown, Robert, Shaw, Christopher E. , Andersen, Peter Munch , Groen, Ewout J. N. , Es, Michael A. van , Pasterkamp, R. Jeroen , Fan, Dongsheng , Smith, George Davey , Gaunt, Tom R. , Eberle, Michael A. , McLaughlin, Russell L. , Hardiman, Orla , Wray, Naomi , Tsai, Ellen A. , Runz, Heiko , Al‐Chalabi, Ammar

Mayo Clinic

No container title available | March 18, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-322430/v1 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a life-time risk of 1 in 350 people and an unmet need for disease-modifying therapies. We conducted a cross-ancestry GWAS in ALS including 29,612 ALS patients and 122,656 controls which identified 15 risk loci in ALS. When combined with 8,953 whole-genome sequenced individuals (6,538 ALS patients, 2,415 controls) and the largest cortex-derived eQTL dataset (MetaBrain), analyses revealed locus-specific genetic architectures in which we prioritized genes either through rare variants, repeat expansions or regulatory effects. ALS associated risk loci were shared with multiple traits within the neurodegenerative spectrum, but with distinct enrichment patterns across brain regions and cell-types. Of the environmental and life-style risk factors obtained from literature, Mendelian randomization analyses indicated a causal role for high cholesterol levels. All ALS associated signals combined reveal a role for perturbations in vesicle mediated transport and autophagy, and provide evidence for cell-autonomous disease initiation in glutamatergic neurons.
Contamination of Single Fluid-Filled Intragastric Balloons with Orogastric Fluid is not Associated with Hyperinflation: An Ex-vivo Study and Systematic Review of Literature
Hawa, Fadi , McRae, Alison , Vargas, Eric J. , Acosta, Andrés , Bazerbachi, Fateh , Dayyeh, Barham K. Abu

Mayo Clinic

No container title available | March 18, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-318739/v1 Get It

Abstract Background Spontaneous hyperinflation is reported to the Food and Drug Administration as a complication of intragastric balloons. It is postulated that orogastric contamination of the intragastric balloon may cause this phenomenon. We sought to investigate the effects of intentional balloon contamination with gastric contents on intragastric balloon diameter and contents, whether methylene blue plays a role in preventing spontaneous hyperinflation, and review the available literature on spontaneous hyperinflation. Methods Four pairs of balloons with different combinations of sterile saline, contaminants, and methylene blue were incubated in a 37° Celsius water bath for 6 months to simulate physiological conditions with serial measurements of balloon diameter. Our findings were compared against a systematic review across multiple databases to summarize the available literature. Results Balloon mean diameter decreased from 33.5 cm ± 0.53 cm to 28.5 cm ± 0.46 cm (p < 0.0001). No significant differences were seen with the methylene blue group. Only 11 cases were found reported in the literature. Conclusions Despite contaminating intragastric balloons with gastric aspirates, hyperinflation did not occur, and other factors may be in play to account for this phenomenon, when observed. Rates of hyperinflation remain under-reported in the literature. Further controlled experiments are needed.
Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2–Platelet‐Derived Growth Factor Receptor Beta–Yes‐Associated Protein Signaling Axis
Campbell, Nellie A. , O’Brien, Daniel R. , Singer, Mark S., Lemjabbar‐Alaoui, Hassan, Ahn, Keun Soo , Smoot, Rory L. , Rosen, Steven D. , Roberts, Lewis R. , Luo, Xin , He, Li , O'Brien, Daniel R, Roberts, Lewis R , Smoot, Rory L , Campbell, Nellie A , Luo, Xin , He, Li , Torbenson, Michael

Mayo Clinic

Hepatology | March 18, 2021 | Volume: 74 | Issue: 3 | Pages: 1411-1428

10.1002/hep.31817 | PMID 33735525 Get It

Background and Aims Existing therapeutic approaches to treat cholangiocarcinoma (CCA) have limited effectiveness, prompting further study to develop therapies for CCA. We report a mechanistic role for the heparan sulfate editing enzyme sulfatase 2 (SULF2) in CCA pathogenesis. Approach and Results In silico analysis revealed elevated SULF2 expression in human CCA samples, occurring partly through gain of SULF2 copy number. We examined the effects of knockdown or overexpression of SULF2 on tumor growth, chemoresistance, and signaling pathway activity in human CCA cell lines in vitro. Up‐regulation of SULF2 in CCA leads to increased platelet‐derived growth factor receptor beta (PDGFRβ)–Yes‐associated protein (YAP) signaling activity, promoting tumor growth and chemotherapy resistance. To explore the utility of targeting SULF2 in the tumor microenvironment for CCA treatment, we tested an anti‐SULF2 mouse monoclonal antibody, 5D5, in a mouse CCA xenograft model. Targeting SULF2 by monoclonal antibody 5D5 inhibited PDGFRβ–YAP signaling and tumor growth in the mouse xenograft model. Conclusions These results suggest that SULF2 monoclonal antibody 5D5 or related agents may be potentially promising therapeutic agents in CCA.
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review
Koehn, Kelly , Sborov, Douglas W. , Rajkumar, S. Vincent , Kumar, Shaji , McClune, Brian , Mohyuddin, Ghulam Rehman , Rajkumar, S Vincent , Kumar, Shaji K , Mohyuddin, Ghulam Rehman , Abdallah, Al-Ola

Mayo Clinic

American Journal of Hematology | March 18, 2021 | Volume: 96 | Issue: 6 | Pages: 690-697

10.1002/ajh.26166 | PMID 33735453 Get It

AbstractSurrogate endpoints are being used more frequently in randomized controlled trials, even though they do not consistently corelate with patient outcomes. We systemically evaluated the use of surrogate endpoints in multiple myeloma randomized controlled trials over the past 15 years. We searched three databases (Pubmed, Embase, Cochrane) for multiple myeloma randomized controlled trials from January 1, 2005 to December 30, 2019. The primary outcome of our study was the proportion of randomized controlled trials that used overall survival as their primary endpoint. Secondary outcomes included the use of surrogate endpoints, and trends over time, and whether they differed based on study sponsorship. We included 151 randomized controlled trials in our analysis. The primary endpoint was overall survival (OS) in 17 (11.3%) of studies, progression free survival (PFS) or event‐defined endpoints in 91 studies (60.3%) and response‐based endpoints in 44 studies (29.1%). Quality of life was a primary endpoint in only three studies (2%). The use of OS as a primary endpoint decreased from 28.5% of trials from 2005 to 2009 to 5.5% from 2015 to 2019. There has been a decrease in the clinically meaningful endpoint of OS over the past 15 years in multiple myeloma randomized controlled trials. Use of quality of life as a primary endpoint remains exceedingly low. It remains paramount to recognize that the use of surrogate endpoints is imperfect, and care based upon them requires constant physician and patient re‐analysis.
Nanotherapeutics using all-natural materials. Effective treatment of wound biofilm infections using crosslinked nanoemulsions
Li, Cheng-Hsuan , Landis, Ryan F., Nabawy, Ahmed , Tronchet, Tiphaine, Archambault, Danielle , Huang, Rui , Golan, Morgane, Cui, Wei , Mager, Jesse , Schmidt-Malan, Suzannah M., Patel, Robin , Patel, Robin , Makabenta, Jessa Marie , Liu, Yuanchang , Gupta, Akash , Rotello, Vincent M.

Mayo Clinic

Materials Horizons | March 18, 2021 | Volume: 8 | Issue: 6 | Pages: 1776-1782

10.1039/d0mh01826k | PMID 34594564 Get It

All-natural cross-linked nanoemulsions provide effective treatment of wound biofilm infections.
Cerebrospinal fluid lipidomics for biomarkers of Alzheimer's disease
Byeon, Seul Kee , Madugundu, Anil K. , Jain, Ankit , Bhat, Firdous Ahmad , Jung, Jae Hun , Renuse, Santosh , Darrow, Jacqueline , Bakker, Arnold , Albert, Marilyn , Moghekar, Abhay , Pandey, Akhilesh , Pandey, Akhilesh , Pandey, Akhilesh , Byeon, Seul Kee

Mayo Clinic

Molecular Omics | March 18, 2021 | Volume: 17 | Issue: 3 | Pages: 454-463

10.1039/d0mo00186d | PMID 34125126 Get It

Abstract Alzheimer's disease (AD) is the most common cause of dementia and is associated with serious neurologic sequelae resulting from neurodegenerative changes. Identification of markers of early-stage AD could be important for designing strategies to arrest the progression of the disease. The brain is rich in lipids because they are crucial for signal transduction and anchoring of membrane proteins. Cerebrospinal fluid (CSF) is an excellent specimen for studying the metabolism of lipids in AD because it can reflect changes occurring in the brain. We aimed to identify CSF lipidomic alterations associated with AD, using untargeted lipidomics, carried out in positive and negative ion modes. We found CSF lipids that were significantly altered in AD cases. In addition, comparison of CSF lipid profiles between persons with mild cognitive impairment (MCI) and AD showed a strong positive correlation between the lipidomes of the MCI and AD groups. The novel lipid biomarkers identified in this study are excellent candidates for validation in a larger set of patient samples and as predictive biomarkers of AD through future longitudinal studies. Once validated, the lipid biomarkers could lead to early detection, disease monitoring and the ability to measure the efficacy of potential therapeutic interventions in AD.
Landmarks of human embryonic development inscribed in somatic mutations
Bizzotto, Sara , Dou, Yanmei , Ganz, Javier , Doan, Ryan N. , Kwon, Min‐Seok , Bohrson, Craig L. , Kim, Sonia N. , Bae, Taejeong , Abyzov, Alexej , Network, NIMH Brain Somatic Mosaicism, Park, Peter J. , Galor, Alon , Yang, Xiaoxu , Kwon, Minseok , Walsh, Christopher A , Abyzov, Alexej , Bae, Taejeong , Park, Peter J , Network, NIMH Brain Somatic Mosaicism, Walsh, Christopher A.

Mayo Clinic

Science | March 18, 2021 | Volume: 371 | Issue: 6535 | Pages: 1249-1253

10.1126/science.abe1544 | PMID 33737485 Get It

Mutations provide an enduring record Somatic mutations pepper our cells with change, but because they are not in the germline, they do not propagate to the next generation. Bizzotto et al. leveraged data on the distribution of somatic mutations in adults to take a backward look at the earliest moments of human development. Calculation of cellular lineages on the basis of shared somatic mutations shows the number of cells from which the body will develop when the human embryo gastrulates. The lineage for forebrain cells is identifiable, as are the asymmetrical fates spun out of many of the gastrula cells. Science , this issue p. 1249
Early developmental asymmetries in cell lineage trees in living individuals
Fasching, Liana , Jang, Yeongjun , Schreiner, Jeremy D. , Tomasini, Livia , Brady, Melanie , Bae, Taejeong , Sarangi, Vivekananda , Vasmatzis, Nikolaos , Wang, Yifan , Szekely, Anna , Fernandez, Thomas , Leckman, James F. , Abyzov, Alexej , Vaccarino, Flora M. , Schreiner, Jeremy , Tomasini, Livia , Brady, Melanie V , Bae, Taejeong , Vasmatzis, Nikolaos , Wang, Yifan , Szekely, Anna , Fernandez, Thomas V , Abyzov, Alexej , Vaccarino, Flora M , Leckman, James F , Jang, Yeongjun , Tomasi, Simone

Mayo Clinic

Science | March 18, 2021 | Volume: 371 | Issue: 6535 | Pages: 1245-1248

10.1126/science.abe0981 | PMID 33737484 Get It

Genomic sleuthing spots early divergence After fertilization, the human zygote divides into two cells. Fasching et al. used genomic analysis from cellular samples taken much later in development to back-calculate the cell division trees that went before. Although the first cell division in human development looks symmetrical from the outside, the fates followed by daughter cells from each of those first two blastomeres are anything but the same. As much as 90% of blood cells are derived from just one of the first two blastomeres. Science , this issue p. 1245